Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cervical Cancer, Cancer, Women's Studies |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 12/8/2018 |
| Start Date: | March 27, 2014 |
| End Date: | December 2020 |
A Phase II Study for Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer (LACC)
The purpose of this study is to determine whether SABR boost therapy is effective in women
with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI)
or genitourinary (GU) toxicity.
with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI)
or genitourinary (GU) toxicity.
Patients enrolled in this study will receive 45 Gray (Gy) in 25 fractions of intensity
modulated external beam radiation therapy + weekly cisplatinum . Following the completion of
Intensity Modulated Radiation Therapy (IMRT), patients will receive 28 Gy in 4 fractions
using stereotactic body radiation therapy techniques.
modulated external beam radiation therapy + weekly cisplatinum . Following the completion of
Intensity Modulated Radiation Therapy (IMRT), patients will receive 28 Gy in 4 fractions
using stereotactic body radiation therapy techniques.
Inclusion Criteria:
1 Locally Advanced stage Cervical Cancer 2. Zubrod performance status 0-2 3. Negative urine
or serum pregnancy test for women of child-bearing potential 4. Agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to study
entry and for the duration of study treatment 5. Not a candidate for intracavitary
brachytherapy
Exclusion Criteria:
1. Pregnancy
2. Concurrent untreated cancer excluding non-Melanoma skin cancer
3. Previous pelvic radiation
4. Active Inflammatory Bowel disease, Collagen vascular disease - systemic lupus
erythematosus (SLE), scleroderma
5. Age <18
6. Unable to consent for study
7. Severely immunocompromised patients ( such as Transplant , on immunosuppressive drugs)
We found this trial at
1
site
1801 Inwood Rd
Dallas, Texas 75390
Dallas, Texas 75390
(214) 645-3300
Phone: 214-645-8525
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Click here to add this to my saved trials
